BSBE(SZ:300406) Sou Hu Cai Jing·2026-01-28 10:16Group 1 - The company expects a net profit attributable to shareholders of 180 million to 218 million yuan for the full year of 2025 [1] - The decline in profit is attributed to asset impairment provisions, with an estimated goodwill impairment provision of approximately 180 million yuan due to increased competition and policy impacts in the medical industry [1] - The company is undergoing goodwill impairment testing, which will be finalized after evaluation by qualified assessment and auditing institutions [1] Group 2 - The company's main business in the in-vitro diagnostics industry is facing pressure from policy changes, leading to a projected net profit of 360 million to 398 million yuan for 2025, a decrease of 25% to 32% year-on-year [2] - The company is actively developing its pathology business, optimizing its business structure, and enhancing its product line through new product development and cost reduction strategies [2] - Non-recurring gains and losses are expected to impact net profit by 7.07 million yuan in 2025, compared to 12.08 million yuan in the previous year [2] Group 3 - For the first three quarters of 2025, the company reported a main revenue of 1.012 billion yuan, a year-on-year decline of 18.24%, and a net profit of 272 million yuan, down 27.03% year-on-year [3] - In Q3 2025, the company’s single-quarter main revenue was 343 million yuan, a decrease of 17.39% year-on-year, with a net profit of 97.23 million yuan, down 20.96% year-on-year [3] - The company reported a debt ratio of 24.55%, with investment income of -1.04 million yuan and financial expenses of 31.04 million yuan, while maintaining a gross profit margin of 79.86% [3]